Acceptability Study of a New Paediatric Form of Vigabatrin in Infants and Children With Infantile Spasms or Pharmacoresistant Partial Epilepsy. Observational, Descriptive, Open-label, Multi-centric, Non-randomized Study
Phase of Trial: Phase II
Latest Information Update: 27 Apr 2018
Price : $35 *
At a glance
- Drugs Vigabatrin (Primary)
- Indications Infantile spasms; Partial epilepsies
- Focus Therapeutic Use
- Acronyms SoluWest
- Sponsors ORPHELIA Pharma; Targeon
- 31 Aug 2018 Biomarkers information updated
- 23 Apr 2018 Status changed from recruiting to completed.
- 27 Feb 2018 According to the ORPHELIA Pharma media release, results of this study were presented at the congress of the French Pediatric Neurology Society.